# US 10,946,085 B2 · Streptococcus uberis extract as an immunogenic agent > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,946,085 B2 - Document ID: US10946085B2 - Status: Granted - Kind: B2 - Application number: 16/075,092 - Filed: 2017-02-14 - Published: 2019-02-07 - Granted: 2021-03-16 - Earliest claimed: 2016-02-15 - Assignees: Hipra Scientific, S.L.U. - Applicants: Hipra Scientific, S.L.U. - Inventors: Rosa Maria Collado Gimbert; Antoni Prenafeta I Amargós - Web page: https://patentgrep.com/patent/US10946085B2 ## CPC - A61K 39/092: {Streptococcus} - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants - A61P 31/04: Antibacterial agents - C12N 1/20: Bacteria; Culture media therefor - C12N 1/36: Adaptation or attenuation of cells - A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to an extract of Streptococcus uberis as an immunogenic agent. It also relates to a process for obtaining said agent which comprises incubating a biofilm-producing S. uberis strain to obtain a biofilm and thermally treating the biofilm obtained. It relates also to a pharmaceutical composition comprising teichoic acids, preferably lipoteichoic acids, for use in the prevention and/or treatment of mastitis and/or infections caused by Streptococcus sp. or by biofilm-producing bacteria. The present invention also relates to a vaccine which comprises said immunogenic agent and to said vaccine and immunogenic agent for use in the prevention and/or treatment of infections caused by Streptococcus sp., especially in the prevention and/or treatment of mastitis caused by S. uberis. It also relates to a vaccination kit which comprises said agent or vaccine. ## Claims ### Claim 1 An immunogenic agent comprising a soluble extract of a heat-treated biofilm, wherein the soluble extract of the heat-treated biofilm is obtained by a process comprising: a) incubating a biofilm-producing S. uberis strain in a culture medium to obtain a biofilm, b) recovering the biofilm from the culture medium and discarding the culture medium and bacterial cells in suspension, c) subjecting the biofilm obtained in step b) to a heat treatment carried out at a temperature comprised from 80° C. to 130° C., and, d) discarding the insoluble fraction obtained after the heat treatment of step c) and preserving the soluble extract, wherein the soluble extract of the heat-treated biofilm thereby is the immunogenic agent. ### Claim 2 (depends on 1) A vaccine comprising an immunologically effective amount of the immunogenic agent of claim 1. ### Claim 3 (depends on 2) The vaccine according to claim 2, characterized in that it further comprises a pharmaceutically acceptable vehicle and/or a pharmaceutically acceptable adjuvant. ### Claim 4 (depends on 3) The vaccine according to claim 3, characterized in that it comprises an adjuvant selected from aluminum hydroxide, aluminum phosphate, aluminum oxide, muramyl dipeptides, vitamin E, squalane, squalene, ginseng, zymosan, glucans, dimethylaminoethyl-dextran, dextrans, non-ionic block polymers, monophosphoryl lipid A, saponins and mixtures thereof. ### Claim 5 (depends on 2) The vaccine according to claim 2, characterized in that it is administered by an intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous or intramammary route. ### Claim 6 (depends on 2) The vaccine according to claim 2, characterized in that it is administered in more than one dose. ### Claim 7 (depends on 2) The vaccine according to claim 2, characterized in that it comprises an additional immunogenic agent from a microorganism selected from the group consisting of: Streptococcus agalactiae, Staphylococcus aureus, Klebsiella sp., Mycoplasma bovis and Escherichia coli. ### Claim 8 A process for the preparation of an immunogenic agent, characterized in that it comprises the following steps: a) incubating a biofilm-producing S. uberis strain in a culture medium to obtain a biofilm, b) recovering the biofilm from the culture medium and discarding the culture medium and bacterial cells in suspension, c) subjecting the biofilm obtained in step b) to a heat treatment carried out at a temperature comprised from 80° C. to 130° C., and, d) discarding the insoluble fraction obtained after the heat treatment of step c) and preserving the soluble extract, wherein the soluble extract of the heat-treated biofilm thereby is the immunogenic agent. ### Claim 9 (depends on 8) The process according to claim 8, characterized in that the incubation is carried out at an atmosphere comprising from 1% to 10% carbon dioxide.